The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To determine whether there is a role for the selective serotonin reuptake inhibitors,
fluoxetine, as therapy in the treatment of refractory primary monosymptomatic nocturnal
enuresis in children , and whether there are side effects involved.